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1. Introduction 
Bivalent cations play a lot of roles in human brain. Calcium, magnesium zinc ,copper and 
other cations are involved in normal functions of the brain .The most important mechanisms 
of action for cations are : modulation of the presynaptic release of some neuromediators , 
influence on neuronal ionic channels, induction of changes in some receptors activity, 
influence on the transporters of neuromediators. The disbalance in intracellular or extra 
cellular concentrations of brain cations are observed in neurological and psychiatric diseases 
(major depression, schizophrenia, heroine addiction, neurodegenerative diseases, 
convulsive disorders). The bipolar disorder( BP ) is a major public health problem. The 
economic cost is high and the patients have a high risk of suicide( Antelman et al. 1998) BD 
also called manic-depressive psychosis is a relative frecvent psychiatric ill. The pathogenic 
mechanism of the development of BD is unknown yet. The aetiopathogenesis of BD will be 
better elucidated in the future by experimental and clinical studies.  
2. Bipolar cations in bipolar disorders 
There are few data , sometimes contradictory regarding the variation of concentration of 
bivalent cations in the patients with BD. Herzberg & Herzberg 1977 observed a decreased 
level for plasma magnesium in BD patients compared to healthy control group. Carman et 
al. 1979 found an increased plasma ratio calcium/ magnesium in BP patients correlated to 
the intensity and duration of maniacal agitation. The plasma zinc levels were decreased in 
acute maniacal agitation. Contrary, Frazer et al. 1983 found a higher erythrocyte magnesium 
level in BD patients not correlated with the severity of clinical symptoms . George et al.1994 
showed an increased level of cerebro-spinal fluid magnesium and lack of correlation with 
the clinical course of mood modulators therapy. Our data (Nechifor et al 2006,2007) show 
that adult patients with bipolar disorder type I presenting acute maniacal attacks and no 
previous treatment exhibit lower intracellular magnesium levels than control group. 
Plasmatic zinc concentrations was significantly lower . There were no significant differences 
between patients with bipolar disorder type I and control group regarding total magnesium 
plasma concentration.. An exaggerated intracellular calcium level and an exaggerated of 
cytosolic calcium concentration in response to serotonin are showed in depressive phase of 
BD and in major depression. Brown et al .2007 observed clinical maniacal symptoms in the 
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cases of hyperthyroidism in patients with hypercalcemia. The plasma zinc levels were 
decreased in acute maniacal agitation The existence of many clinical forms of BD contributes 
to the heterogeneity of obtained data 
3. Our studies on bivalent cations level in patients with bipolar disorders  
After DSM IV bipolar disorders are classified in four groups. In the bipolar disorder type I 
the patient has mixed maniac and depressive symptoms with at least one maniac episode. 
All the patients from our study have been the type I bipolar disorder patients. The mood 
modulators are the treatment of choice today for BD. Some anticonvulsivant drugs are the 
main choice drugs today in BD treatment (Goodnick 2006,Muzina et al. 2005, Bowden et al. 
2006 ). Carbamazepine and sodium valproate are usually used in BD therapy(Weisler et 
al.2005, Walden et al. 1993 )The aim of our research was the determination of the plasma 
and the intracellular levels of some bivalent cations in BD patients before the treatment and 
also the study of the influence of mood modulators influence on cations concentration 
during BD therapy. We determined the levels of plasma calcium , magnesium , copper and 
zinc and the erythrocyte magnesium concentration in adult patients with BD type I ( after 
DSM IV). We worked on adult patients with bipolar disorders (BD)(diagnosed after DSMIV 
criteria) ageing 21-58 years Admitted into “Socola Psychiatric Hospital” Iasi Romania. In the 
study were included only type I BD adult patients hospitalized during the maniacal episode 
.We worked on three groups of patients : I group received carbamazepine 600mg/day p.o. 
daily 4 weeks ; IInd group received sodium valproate 900mg/day p. o. daily 4 weeks ; IIIrd 
group received quetiapine 400-600mg/day p.o.daily 4 weeks. A group of 20 healthy adults 
was control group.  
Including criteria: bipolar disorder (diagnosed after DSM IV), at least 4 weeks treatment, 
absence of anyone BD treatment before admittance in hospital. All patients did not received 
any treatment for BD before hospitalization . The following non-including criteria were 
used: pregnancy, lactation, renal failure , heart failure, hepatic failure malabsorbtion 
syndrome, treatment with bivalent cations containing drugs or diuretics treatment. The 
plasma levels of total calcium ,total magnesium, zinc and copper and erythrocyte 
magnesium level were determined by atomic absorbtion spectrofotometry. The 
determination was performed before the start of treatment and after 4 weeks. In this study 
were included only patients with at least 4 weeks hospitalization. The results were statistic 
interpreted.  
3.1 Results 
The obtained date showed that zinc plasma level was decreased in BD patients before 
treatment compared to control group. (0.89±0.12mg/l in control group vs. 0.62±0.05mg/l in 
BD group p<0.05 ). No changes in total calcium plasma concentration( 116. 32±9,1 mg/l in 
BD patients vs. 109.20±12.3mg/l in control group ). The erythrocyte magnesium level was 
decreased in BD patients before treatment ( 45, 01±1.67mg/l in PD patients vs 59.15 
±2.01mg/l in control group p< 0.05 ). The copper concentration was increased in BD patients 
before treatment compared to control group ). After 4 weeks of treatment the plasma zinc 
concentration increased in all group of treated patients ( ex. after sodium valproate , Zn 
concentration was 0.83±0.04mg/l p< 0.05 )The erythrocyte magnesium level increased in all 
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treated patients ( ex. in carbamazepine group after treatment Mg concentration was 53.72 
±2.18mg/l p < 0.05 ),but only in quetiapine treated group , the total plasma magnesium 
concentration significantly increased. In all treated groups copper plasma concentration 
decreased after the treatment Did non changes in calcium plasma levels after mood 
modulators treatment. Our results showed that zinc plasma concentration and erythrocyte 
magnesium level are decreased during the maniacal acute episode of type I BD patients . 
The obtained data showed that different mood modulator with different mechanism of 
action increased zinc plasma level and decreased copper plasma concentration. The 
erythrocyte magnesium is also increased. There are good positive correlations between the 
improvement of clinical status of patients and the increase of zinc plasma concentration and 
the augmentation of intracellular magnesium levels. 
4. Intractions between mood modulator and bivalent cations 
4.1 Magnesium  
The mood modulators used in the treatment of BD induced important changes in some 
bivalent cations concentrations. The increase of magnesium intracellular concentrations 
were observed after all three mood modulators used. There are data showed that lithium , 
the oldest effective drug for the treatment of maniac-depressive illness increases the 
intracellular magnesium levels .Most studies show that the repeated lithium salts 
administration increases the magnesium concentration. 
Lithium increases the intracellular magnesium concentration by competition between 
magnesium and lithium for some intracellular binding sites(Leyden et al.2000, Mota de 
Freitas et al.2006 )After experimental loading of neuroblastoma cells with 1-2 mM of 
extracellular Li+, the intracellular free magnesium concentration was significantly higher . 
Regarding the Li+-Mg2+ competition at some intracellular sites , the existing data indicate 
the following targets :molecules:inositol monophosphatase, glycogen syntase kinase(GSK 3), 
fructose 1,6 biphosphatase, biphosphate nucleotidase , ADP and ATP phosphate bindind 
sites but it is possible to be also and other intracellular binding sites for this competition.( 
Gould et al. 2004)  
The main ways for magnesium action in BD are :a)decreasing the neuronal response to 
glutamate overstimulation by blocking the calcium channel coupled with NMDA 
receptors;b) the decreasing presynaptic release of some excitatory neuroaminoacids; c) 
modulator action at the level of gabaminergic and serotoninergic systems. Gobbi & Janiri 
,2006 showed that magnesium-valproate significantly modulates the response induced by 
NMDA-receptor stimulation. Chuinard et al. 1990, showed that magnesium aspartate 
administration was effective in stabilizing the mood of rapid-cycling BD which favor the 
idea that the increase in magnesium concentration is an important factor of lithium and 
other mood modulators mechanism of action. Magnesium oxide increases the verapamil 
maintenance therapy in mania (Giannini et al 2000). This fact favors the idea that an increase 
in magnesium concentration is an important fact, maybe essential for the therapeutic effect 
of some drugs used in BD treatment. Magnesium-valproate reduces the hyperactivity in an 
animal model of mania. This effect of magnesium valproate could be abolished by 
bicuculine.These findings suggest that the action on the postsynaptic GABA effect may be 
involved also in magnesium-valproate antimaniacal action (Cao & Peng , 1993). The 
www.intechopen.com
 Bipolar Disorder – A Portrait of a Complex Mood Disorder 
 
6 
neuroprotective magnesium effect in CNS is important not only for the recovery process 
after various injury( Vink & Cernak 2000 ) but also to reduce the maniacal agitation. 
Machado-Viera R. et al. 2009 showed that the neurotrophic effect of lithium is very 
important for neuro protection (Rowe & Chuang 2004 ) and for prophylaxis of acute mood 
effects and one of the main targets of lithium intracellular action is GSK-3 . By action at the 
level of this enzyme, Li increase the intracellular level of magnesium. It is possibil that ,at 
least in part ,the reduction of apoptosis by lithium is produced by magnesium ions which 
inhibit the apoptosis. There are few studies about the magnesium alone effect in the 
treatment of bipolar disorders. Chouinard et al. 1990 showed a moderate effect of 
magnesium treatment as mood stabilizer for rapid cycling bipolar affective patients .An 
other way to explain the the effect of magnesium and zinc in BP disorders is the antioxidant 
effect. The oxidative stress is increased in animal models of mania produced by 
amphetamine administration. .Chronic amphetamine treatment is associated with an 
imbalance in SOD and CAT activity. In experimental studies in rats lithium and valproate 
prevented the excitotoxicity by reducing the oxidative stress (Shao et al. 2005 ) The both 
magnesium and zinc have an antioxidant effect.An other target for magnesium involvement 
in mood stabilizers therapeutic effect is BDNF ( brain derived neurotrofic factor ).The mood 
modulators (Frey et al. 2006) but also magnesium increase the BDNF concentration . The 
ratio between calcium and magnesium and the antagonist effect of magnesium regarding 
some calcium action are essential for explanation of importance of magnesium in 
mechanism of mood modulators effects. The transmembrane calcium influx plays an 
important role in the development of some psychiatric disorders. In BD has been observed 
dysfunctions in the intracellular signaling transduction ,altered calcium signaling and a 
elevated protein kinase A activity ( Langan & McDonald 2009 ). 
The calcium channels antagonists (verapamil and others) raise carbamazepine effect. 
Magnesium, acting like a natural calcium antagonist on some ionic channels is a factor 
which contributes at the pharmacodinamic effect of some mood modulators. Contrary, the 
calcium ions have an antagonic effect on carbamazepine action. Carbamazepine reduces the 
neuronal excitability and glutamate release and we consider that this effect is due at least in 
part by increasing the magnesium concentration. The alteration of calcium homeostasis is 
involved in the onset or progression of various neurological and psychiatric diseases.such as 
Parkinson’s disease, Alzheimer’s and others degenerative diseases, bipolar disorders, 
Hutington’s disease and others (Salvaraj et al. 2010).The hypercalcemia and the change of 
the ratio calcium/ magnesium could be involved in the pathophysiology of bipolar 
disorder. Maniacal clinical symptoms from hyperparathyroidism are mediated by 
hypercalcemia .The patients with maniacal symptoms had have a high level of calcium in 
the blood and cerebrospinal fluid. The bipolar disorder is not the single disease in which are 
involved calcium signaling abnormalities in the central nervous system. Cytosolic Ca2+ 
signals are correlated to extracellular calcium enters through plasma membrane channels 
and to the calcium release from the intracellular stores .In some diseases as seizures, 
migraine and autism is possibil to be genetic calcium signaling abnormalities(Gargus .2009).  
The main mechanism of action of mood modulators in BD is the reduction of the 
glutamatergic systems activity via NMDA receptors activation. The key common point of 
magnesium and zinc action in BD is NMDA glutamate receptors. Magnesium ions and some 
calcium antagonists act also at the level of NMDA receptors coupled calcium channel  
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The changes in calcium homeostasis are important in the pathophysiology of the bipolar 
disorder.( Akimoto et al. 2007 ) . Calcium enhance NMDA receptor activity and stimulate 
the presynaptic glutamate release. There are evidences of abnormalities in intracellular 
calcium distribution, concentration and activity and for the involvement of calcium 
homeostasis disregulation in the molecular mechanism of this disease. Perova T. et al. 
2007 showed a hyperactive intracellular calcium dynamics in the lympoblasts from 
patients with type I bipolar disorder. Acting as a calcium antagonist, magnesium can 
reduces in part calcium effects in bipolar disorders. Yasuda et al.2009) showed that for 
mood modulators as valproic acid and lithium ,the GSK-3 inhibition and the stimulation 
of brain-derived neurotrophic factor(BDNF )synthesis are the primary targets in the 
action mechanism involved in the suppression of bipolar disorders symptoms. BDNF is 
strongly involved in the synaptic plasticity, reduces the apoptosis , increase the neuronal 
survival and regulates the expression of NMDA receptors in brain ( Caldeira et al 2007) 
Magnesium is also involved in neuronal plasticity, inhibits the apoptosis and reduces the 
neurotoxicity of high glutamate concentration and of overstimulation of NMDA 
receptors. The kainat-induced neurotoxicity is produced after stimulation of NMDA 
receptors and lithium decreases this toxicity.Also the NMDA receptors mediated 
neuronal vacuolization is attenuated by mood modulators( Bown et al. 2003).Crespo-Biel 
et al.2010 showed that this neuroprotective effect is produced by modulation of calcium 
entry in neurons. By reducing the calcium penetration in the cell, magnesium can be 
involved in the neuroprotective lithium effect. The mood modulators have also an 
important antiapoptotic action (Chuang et al.2005). Magnesium has a important 
antiapoptotic action and can be involved in this action of mood modulators.We belive 
that the increase of intracellular magnesium concentration is also a primary step in mood 
modulators mechanism of action.Bipolar disorder patients have a high rate of relapse( 
Newberg et al.2008). The Ca2+- permeable melastin related transient receptor potential 2 
(TRPM2 ) channels are important for the entry of calcium ions into the cell.The genetic 
variations of TRPM 2 increases the risk of devoloving bipolar disorders ( Naziroglu 
2011)There are data implicating L-type calcium channels disfunctions in the 
pathophysiology of neuro psychiatric disorders.( Casamassima et al.2010).In mood 
disorders, L-type calcium channels blockers reduced in clinical practice the intensity of 
clinical symptoms. In the animal models of depression the calcium channels blockers had 
have a similar effect. Glutamate stimulates NMDA receptors and increases the entry of 
calcium in neurons. Verapamil , a calcium channels antagonist augmented the lithium 
effects in the treatment of mania. In some studies , verapamil alone has shown 
antimaniac effect. ( Mallinger et al. 2008 ), but the verapamil monotherapy has a reduced 
efficacy in BD type I patients. In the experimental model of depression induced by forced 
swim test in rats and in the tail suspension test in mice, zinc administration exerts an 
antidepressant effect (Kroczka et al. 2001, Rosa et al. 2003). Magnesium oxide increases 
the verapamil maintenance therapy in mania (Giannini et al 2000). This fact favors the 
idea that an increase in magnesium concentration is an important fact, maybe essential 
for the therapeutic effect of some drugs used in BD treatment. Magnesium-valproate 
reduces the hyperactivity in an animal model of mania. This effect of magnesium 
valproate could be abolished by bicuculine.These findings suggest that the action on the 
postsynaptic GABA effect may be involved also in magnesium-valproate antimaniacal 
action (Cao & Peng , 1993). 
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Lithium improves the cognitive deficits in animal models of neurodegenerative diseases. 
Magnesium also increases the memory in experimental studies. It is possibil that , in part , 
the cognitive effect of lithium be intermediated by the increase of magnesium intracellular 
concentration. 
Magnesium potentiates the effects of anxiolitics. There are experimental evidences of the 
potentiation of anxiolytic effect of diazepam by magnesium aspartate (Borzeix et al. 
1991). 
To the extent that glutamatergic signaling via NMDA receptors is pathologically 
upregulated in bipolar disorder patients, ( Toro & Deakin 2005, Hashimoto et al. 2007) The 
modulation of signal transduction at the level of glutamate, serotonin, dopamine and GABA 
receptor by the mood modulators has major therapeutic involvements ( Manji et al. 1999) 
Valproic acid interferes with glutamatergic function and NMDA receptor signaling., 
Valproic acid acts at the level of NMDA receptors by different ways ( Gean et al.1994). This 
drug reduces induction of Fos and of activator protein-1 DNA binding activity. By this mean 
is modulated the transcription of the NMDA receptor subunit, NR2B. Chronic valproate 
treatment blocks D(2)- receptor-mediated brain signaling via arachidonic acid in rats.By 
inhibiting NMDA receptors mediated calcium influx ,lithium and magnesium suppresses 
the calcium dependent way for activation of apoptotic signaling pathways(Chiu & 
Chuang2011 ) Lamotrigine is an other mood modulator used in bipolar disorder which has a 
key point of mechanism of action the blocking effect of NMDA receptor mediated signaling 
in the brain ( Ramadan et al 2011 ).  
Substances that interfere with dopaminergic (Murphy et al. 1971) or glutamatergic ( 
Anand et al. 2000) signaling ameliorate bipolar disorder symptoms. Bipolar symptoms 
reflect reduced cholinergic( Bymaster et al. 2002), altered serotonergic, and increased 
dopaminergic and glutamatergic neurotransmission.The mood-stabilization of bipolar 
patients appear only after 10 days or more time administration. We thing that the 
retardation of effect appears because needs time for increasing the intracellular 
magnesium concentration. Our data showed a good positive correlation between 
therapeutic effect and the increase the intracellular but not with the extracellular 
magnesium concentration. The acute administration of a single dose of mood modulators 
don’t change the glutamate level but also don’t modify the magnesium concentration. The 
therapeutic effect of carbamazepine in the treatment of epilepsies and in affective 
disorders was decreased by a low magnesium level in patients effect (Walden et al. 
1993).An other possibility for magnesium beneficial effect in the treatment of BD by 
various mood modulators is action at the leval of GABA-ergic systems from the CNS. 
Magnesium valproate decreased the hipermotility in experimental rodent model of mania 
but this effect is diminished by bicuculline , substance which blocks GABA receptors.( 
Cao & Peng 1993) This fact involves the post synaptic GABA receptors in magnesium 
effect in BD.Magnesium can modulate the GABA receptors activity and there are evidence 
for a potentiating effect of magnesium at the level of GABA A receptors (Moykkynen et al 
.2001).The interactions between magnesium and lithium are very complex because there 
are possibilities that magnesium increase the lithium entry into the cells.( Rybakowski & 
Szajnerman 1976).  
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The increase of copper level could be also involved in the pathogenesis of bipolar disorders. 
Mood disorders are frecvent reported in Wilson disease. Maniac symptoms and depressive 
behevior are present in patients which high level of copper. (Keller et al. 1999, Akil & 
Brewer 1995).In 20% of patients, the psychiatric manifestations preceded all other 
symptoms. ( Dening & Barrios 1989 , Machado et al..2008). The mechanism of action of 
increased copper concentration in mood disorders is not clear but we beleve that the 
influence on dopamine neuromediation and the possible increase of glutamatergic system 
activity is important. Studies performed in rats showed that copper has an opposite effect on 
the compared to magnesium and zinc. Copper-dopamine complex induced mitochondrial 
autophagy and the neuronal death( Paris et al. 2009 ). In the same time, the stimulation of 
synaptic NMDA receptors by glutamate in hippocampus neurons is associated to the release 
of copper from intracellular stocks .A copper efflux after NMDA receptors activation was 
observed.. Unlike magnesium and zinc, copper could function as a metal involved in 
nitrosylation of NMDA receptors. Surely, copper is a neuromodulator factor of some brain 
area as hippocampus. 
GABA is one of the factors involved in the reduction in intensity of opiate dependence, as 
well as in the reduction in intensity of opiate-withdrawal syndrome signs. At least in some 
brain areas, copper blocks GABA receptors . Copper and zinc interact al the level of GABA 
receptors (Sharonova et al. 2000) The copper-GABA complex antagonized diazepam 
anticonvulsivant effect (Kardas et al 1984). This shows that by forming a complex with 
GABA, copper ions reduce the efficacy of this amino-acid in antagonizing glutamate effects 
during the development of morphine dependence.  
4.3 Zinc  
Zinc allosteric modulates the 5-HT (1A ) serotonin receptors( Barrondo & Salles 2009 )By this 
way ,zinc can be an importantfactor influencing the antidepressant and mood modulators 
therapy.This cation modulates also the neurotransmitters activity including dopamine and 
serotonin transporters. (Norgaard-Nilsen & Gether 2006) Regarding main ways by which the 
increase of zinc concentration can be involved in the mechanism of mood modulators action , 
very important is zinc effect on the NMDA receptors . By stimulation of NMDA receptors 
glutamate induces agitation and anxiety . Zn2+decreases the NMDA receptor stimulation. 
Increased zinc concentration in amigdala decreases the fear and the anxiety (Takeda et al 
2010). The antidepressant action involved also the serotoninergic system ( Szewczyk et al. 
2009, Garcia-Colunga et al. 2005 ).. Serotonin is a big target for antidepressant drugs( Harvey 
1997). An important number of very used antidepressant drugs are substances which block 
serotonin re-uptake. The chronic lithium treatment influences the cortical serotonin uptake 
and 5-HT1A receptors activity(Carli et al.1997).Zinc modulates the lithium induced 
biochemical and behavioral changes in rats(Bhalla et al. 2007) 
Zinc modulates the serotonin uptake in some areas from the brain . The effects of fluoxetine, 
imipramine and 6-nitroquipazine on serotonin uptake in rat brain are modulated by zinc ( 
Garcia-Colunga et al. 2005).Serotonin induced platelet calcium mobilization is enhanced in 
BD patients (Okamoto et al. 1995, Akimoto et al .2007). In the experimental model of 
depression induced by forced swim test in rats and in the tail suspension test in mice, zinc 
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administration exerts an antidepressant effect (Kroczka et al. 2001, Rosa et al. 2003, Opoka et 
al. 2009) . There are experimental data about a complex zinc-induced adaptative and 
modulatory changes in glutamateric and serotoninergic brain systems( Cichy et al. 2009 ).In 
our clinical studies (Nechifor et al. 2004, Nechifor 2008) the plasma zinc concentration was 
decreased and the antidepressant treatment augmented the level of this cation. Chronic 
lithium administration reduced the NMDA receptors signaling  also via arachidonic acid 
and eicisanoids synthesis(Basselin et al. 2006)but is not clear if zinc or magnesium influence 
this way. 
4.4 Calcium  
Calcium ions play a very important role in biological signal transduction, in synthesis and 
release of neuromediators and neuromodulators and in the several enzymes activity.The 
calcium neuronal activity in bipolar disorders is increased.There are studies which showed 
that a elevation of basal calcium intracellular concentration in B D patients (Emamghoreishi 
et al .1997, Du et al. 2004 ) . 
A way for the involvement of calcium in bipolar disorders pathogeny is PKC activity. This 
enzyme potentiates the the response after NMDA receptors stimulation by increasing the 
calcium entry by the channel coupled with NMDA receptors and by reducingthe voltage –
dependent magnesium block of this channel (Chen & Huang 1992 )PKC also up-regulates 
the function of L-type calcium channels and the entry of calcium into the cell(McCarty 2006). 
Magnesium can decrease this mechanism involved in BD. Valproate, lithium and other 
mood modulators decrease also the PKC activity( Mallinger et al.2008) .The increase of 
intracellular magnesium concentration can be a common point for the antimaniacal and 
antidepressive action. 
5. Conclusions 
The increase of intracellular magnesium concentration by different mood modulators which 
various chemical structures and different mechanism of action shows that this is important 
for the therapeutic effect in BD treatment. On the other hand, this magnesium intracellular 
concentration change is associated with an significant augmentation of plasma zinc level 
and decrease of plasma copper concentration We consider that there changes is in important 
part of the mechanism of pharmacotherapeutic action of mood modulators. We believe that 
the bivalent cations disbalances are involved in the B D relapses and also in the reduction of 
efficacy of the mood modulators therapy. 
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